C51細胞

C51是源自BALB/c實驗小鼠的小鼠結腸癌細胞系，目前應用於多項不同類別的研究。

科研用途

2003年，有學者將重組腺病毒AdEndo注射至C51細胞模型，發現內皮抑素（英語：Endostatin）在某些腫瘤細胞系中發揮直接的抗癌作用，期望內皮抑素可應用於某些結腸癌的治療^[1]。2015年，有學者發現放射線療法與抗體融合蛋白L19-IL2結合的治療，可產生持久及高度協同的針對原發性C51細胞的作用，治癒率為百分之七十五^[2]。2018年，有研究指出經輻照的C51腫瘤細胞和未經輻照的CT26腫瘤細胞，具有共同的腫瘤特異性抗原（英語：Tumor antigen）。來自其他來源的繼發性腫瘤可能共享更少數量的抗原，並且對C51細胞引起的嚴重應答反應較少^[3]

參考資料

[1]
Dkhissi, F; Lu, H; Soria, C; Opolon, P; Griscelli, F; Liu, H; Khattar, P; Mishal, Z; Perricaudet, M; Li, H. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells.. Human gene therapy. 2003-07-01, 14 (10): 997–1008 [2019-12-14]. PMID 12869217. doi:10.1089/104303403766682250.
[2]
Zegers, CM; Rekers, NH; Quaden, DH; Lieuwes, NG; Yaromina, A; Germeraad, WT; Wieten, L; Biessen, EA; Boon, L; Neri, D; Troost, EG; Dubois, LJ; Lambin, P. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015-03-01, 21 (5): 1151–60 [2019-12-14]. PMID 25552483. doi:10.1158/1078-0432.CCR-14-2676.
[3]
Rekers, NH; Olivo Pimentel, V; Yaromina, A; Lieuwes, NG; Biemans, R; Zegers, CML; Germeraad, WTV; Van Limbergen, EJ; Neri, D; Dubois, LJ; Lambin, P. The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.. Oncoimmunology. 2018, 7 (4): e1414119 [2019-12-14]. PMID 29632732. doi:10.1080/2162402X.2017.1414119.

[1] [1]
Dkhissi, F; Lu, H; Soria, C; Opolon, P; Griscelli, F; Liu, H; Khattar, P; Mishal, Z; Perricaudet, M; Li, H. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells.. Human gene therapy. 2003-07-01, 14 (10): 997–1008 [2019-12-14]. PMID 12869217. doi:10.1089/104303403766682250.

[2] [2]
Zegers, CM; Rekers, NH; Quaden, DH; Lieuwes, NG; Yaromina, A; Germeraad, WT; Wieten, L; Biessen, EA; Boon, L; Neri, D; Troost, EG; Dubois, LJ; Lambin, P. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015-03-01, 21 (5): 1151–60 [2019-12-14]. PMID 25552483. doi:10.1158/1078-0432.CCR-14-2676.

[3] [3]
Rekers, NH; Olivo Pimentel, V; Yaromina, A; Lieuwes, NG; Biemans, R; Zegers, CML; Germeraad, WTV; Van Limbergen, EJ; Neri, D; Dubois, LJ; Lambin, P. The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.. Oncoimmunology. 2018, 7 (4): e1414119 [2019-12-14]. PMID 29632732. doi:10.1080/2162402X.2017.1414119.

[1]

[2]

[3]